Your browser doesn't support javascript.
loading
Xylazine Adulteration of the Heroin-Fentanyl Drug Supply : A Narrative Review.
D'Orazio, Joseph; Nelson, Lewis; Perrone, Jeanmarie; Wightman, Rachel; Haroz, Rachel.
Afiliação
  • D'Orazio J; Cooper University Healthcare, Camden, New Jersey (J.D., R.H.).
  • Nelson L; Rutgers New Jersey Medical School, Newark, New Jersey (L.N.).
  • Perrone J; University of Pennsylvania, Philadelphia, Pennsylvania (J.P.).
  • Wightman R; Alpert Medical School of Brown University, Providence, Rhode Island (R.W.).
  • Haroz R; Cooper University Healthcare, Camden, New Jersey (J.D., R.H.).
Ann Intern Med ; 176(10): 1370-1376, 2023 10.
Article em En | MEDLINE | ID: mdl-37812779
Xylazine is an animal sedative, approved by the U.S. Food and Drug Administration, that is commonly used in veterinary medicine and is not approved for human use. Since 2016, xylazine has consistently appeared in the illicitly manufactured fentanyl supply and has significantly increased in prevalence, likely due to its low cost, easy availability, and presumed synergistic psychoactive effect. Clinical experience along with the available pertinent research were used to review xylazine adulteration of the drug supply and provide guidance on the care of patients exposed to xylazine. This review discusses xylazine pharmacology, animal and human clinical effects, and what is known to date about care of patients experiencing acute overdose, xylazine-fentanyl withdrawal, and xylazine-associated wounds.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Drogas Ilícitas / Overdose de Drogas Tipo de estudo: Guideline / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Ann Intern Med Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Drogas Ilícitas / Overdose de Drogas Tipo de estudo: Guideline / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Ann Intern Med Ano de publicação: 2023 Tipo de documento: Article